#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stiff person syndrome Mycobacterium abscessus infection Cystic fibrosis gastrointestinal disease Hyperadrenocorticism B-cell lymphoma recurrent Inborn error of metabolism Hodgkin's disease Leiomyosarcoma Chronic myelomonocytic leukaemia Focal segmental glomerulosclerosis Follicular lymphoma stage II Glioblastoma multiforme Immune-mediated myositis Pleomorphic liposarcoma Primary myelofibrosis More trials…

    Learn about Rare Diseases

    Indolent systemic mastocytosis Glycogen storage disease type II – Trials in Disease Lennox-Gastaut syndrome – Diagnostics Hereditary motor and sensory neuropathy – Trials in Disease Alternating hemiplegia of childhood – Life with Disease Atypical haemolytic uraemic syndrome – Basic Information Congenital nephrogenic diabetes insipidus – Treatment Nephroblastoma Wolfram syndrome – Basic Information Rett syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    HSP-CAR19M Pentetic Acid Ulotaront Mva-209-Fsp-B3 Leuprorelin Acetate Encaleret Sulfate L-PROLINE Masupirdine Dornase Alfa Tadalafil Lysine Acetate Citric Acid Etuvetidigene Autotemcel Imiglucerase Venetoclax Altizide Ephedrine Hydrochloride ANOC-001 Edotreotide Clonidine Hydrochloride More therapies…

    Learn about Your Condition

    Low cardiac output syndrome Synovial sarcoma Atrial fibrillation Myositis Lymphocytic lymphoma Polymyositis Pulmonary hypertension Chorea Anaemia of chronic disease Cervix carcinoma stage III Cholangitis sclerosing Merycism Febrile neutropenia Endocrine disorder Infantile spasms More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Ovarian cancer

  • Open‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Avutometinib
    • Defactinib
    France

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • LY4170156
    • Bevacizumab
    Austria Belgium Czechia Denmark France Germany +9

  • A study to evaluate the use of [68Ga]BED003 for imaging colorectal, gastric, pancreatic, breast, and ovarian cancers.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    • Gastric cancer
    • Ovarian cancer
    Italy The Netherlands

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Sacituzumab Tirumotecan
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +9

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    • Doxorubicin Hydrochloride
    • Gemcitabine Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2
1 2 3 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!